The role of belantamab mafodotin in multiple myeloma: the DREAMM-7 and DREAMM-8 trials

The role of belantamab mafodotin in multiple myeloma: the DREAMM-7 and DREAMM-8 trials

Dr Trudel on the Significance of the DREAMM-7 and DREAMM-8 Trials in R/R Multiple MyelomaПодробнее

Dr Trudel on the Significance of the DREAMM-7 and DREAMM-8 Trials in R/R Multiple Myeloma

Dr Krishnan on the Evolving Role of Belantamab Mafodotin in Multiple MyelomaПодробнее

Dr Krishnan on the Evolving Role of Belantamab Mafodotin in Multiple Myeloma

Belantamab mafodotin: a potential new SoC in second-line myeloma based on the DREAMM trialsПодробнее

Belantamab mafodotin: a potential new SoC in second-line myeloma based on the DREAMM trials

ASCO/EHA 2024 Myeloma Highlights- IMROZ, DREAMM-7, DREAMM-8 | Joshua Richter, MD | EHA 2024Подробнее

ASCO/EHA 2024 Myeloma Highlights- IMROZ, DREAMM-7, DREAMM-8 | Joshua Richter, MD | EHA 2024

The future of ADCs in treating multiple myelomaПодробнее

The future of ADCs in treating multiple myeloma